PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL

• Yan Gao,
• Liling Zhang,
• Sujun Gao,
• Yu Yang,
• Qing-Yuan Zhang,
• Huilai Zhang,
• Pengcheng He,
• Fei LI,
• Hongmei Jing,
• Susan Grange,
• Lilian Bu,
• Qianming Wang,
• Yanjie Wang,
• Huiqiang Huang

Affiliations

Yan Gao

1 Sun Yat-Sen University Cancer Center, Internal Medicine, Guangzhou, China

Liling Zhang

2 Union Hospital Tongji Medical College Huazhong University of Science and Technology, Cancer Center, Wuhan, China

Sujun Gao

3 The First Hospital of Jilin University, Hematology, Changchun, China

Yu Yang

4 Fujian Provincial Cancer Hospital, Lymphoma and Head & Neck Oncology, Fuzhou, China

Qing-Yuan Zhang

5 Harbin Medical University Cancer Hospital, Internal Medicine, Harbin, China

Huilai Zhang

6 Tianjin Medical University Cancer Institute & Hospital, Lymphoma, Tianjin, China

Pengcheng He

7 The First Affiliated Hospital of Xi’an Jiaotong University, Hematology, Xi’an, China

Fei LI

8 The 1st Affiliated Hospital of Nanchang University, Hematology, Nanchang, China

Hongmei Jing

9 Peking University Third Hospital, Hematology, Beijing, China

Susan Grange

10 F. Hoffmann-La Roche Ltd, Pharmacology, Basel, Switzerland

Lilian Bu

11 F. Hoffmann-La Roche Ltd, Biostatistics, Shanghai, China

Qianming Wang

12 F. Hoffmann-La Roche Ltd, Clinical Science, Shanghai, China

Yanjie Wang

13 F. Hoffmann-La Roche Ltd, Safety Science, Shanghai, China

Huiqiang Huang

1 Sun Yat-Sen University Cancer Center, Internal Medicine, Guangzhou, China